WASHINGTON (dpa-AFX) - Alkermes plc (ALKS) announced preliminary findings
from a phase 1 clinical trial of ALKS 7119, an oral, novel small molecule that
acts on multiple key receptor systems in the brain. ALKS 7119 is being developed
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.